| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD19; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12; CD19 |
| Entrez GeneID | 930 |
| clone | 11H8 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human CD19 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3-4条关于CD19抗体的参考文献及其简要摘要：
---
1. **文献名称**：*Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia*
**作者**：Maude SL, et al.
**摘要**：该研究发表于《新英格兰医学杂志》(2018)，报道了CD19 CAR-T细胞疗法(Tisagenlecleucel)在复发/难治性B细胞急性淋巴细胞白血病(ALL)儿童及年轻患者中的疗效，显示75%的完全缓解率，奠定了CD19靶向治疗在血液肿瘤中的重要地位。
2. **文献名称**：*Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia*
**作者**：Kantarjian H, et al.
**摘要**：这项III期临床试验(《新英格兰医学杂志》，2017)评估了双特异性CD19/CD3抗体Blinatumomab与化疗的对比，证明其显著延长复发/难治性ALL患者的总生存期(7.7个月 vs 4.0个月)，成为首个获批的CD19靶向双抗疗法。
3. **文献名称**：*Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma*
**作者**：Caimi PF, et al.
**摘要**：该研究(《柳叶刀肿瘤学》，2021)探讨了CD19抗体药物偶联物(ADC)Loncastuximab Tesirine治疗复发/难治性弥漫大B细胞淋巴瘤(DLBCL)的效果，结果显示48.3%的客观缓解率，验证了CD19 ADC的临床潜力。
4. **文献名称**：*CD19 as an attractive target for antibody-based therapy*
**作者**：Gribben JG, et al.
**摘要**：这篇综述(《自然·免疫学评论》，2012)系统总结了CD19在B细胞恶性肿瘤中的生物学功能及其作为治疗靶点的机制，涵盖单抗、CAR-T及双抗等策略的开发进展，为后续研究提供了理论基础。
---
以上文献涵盖CAR-T、双抗、ADC及基础研究，反映了CD19抗体在肿瘤治疗中的多样化应用。
CD19 is a transmembrane glycoprotein predominantly expressed on the surface of B cells, serving as a critical regulator of B-cell receptor (BCR) signaling. As a member of the immunoglobulin superfamily, it acts as a co-receptor with CD21 and CD81. modulating B-cell activation, proliferation, and survival. Its restricted expression to B-lineage cells—from pro-B cells to mature B cells, but absent on plasma cells—makes it an attractive therapeutic target for B-cell malignancies and autoimmune disorders.
In oncology, CD19-targeting therapies revolutionized treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphomas. Chimeric antigen receptor (CAR) T-cell therapies, such as tisagenlecleucel, engineer patient-derived T cells to recognize CD19. achieving remarkable remission rates. Monoclonal antibodies like blinatumomab (bispecific CD19-CD3 antibody) redirect T cells to eliminate CD19+ malignant cells.
Emerging research explores CD19 targeting in autoimmune diseases. By depleting pathogenic autoreactive B cells, CD19-directed therapies show promise in conditions like lupus and rheumatoid arthritis. However, challenges persist, including antigen escape in cancers and prolonged immunosuppression risks. Ongoing studies focus on optimizing efficacy while minimizing toxicity, such as cytokine release syndrome in CAR-T treatments. CD19 remains a cornerstone of B-cell-targeted immunotherapy, with evolving applications across hematology and immunology.
×
